Cordex Biologics Inc.
  • About us
  • Science
  • Clinical Trials
  • News
  • Contact
  • English
    • Français
    • English
Select Page

ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy

by admin | Jun 4, 2024 | English

– UM171 Cell Therapy has been granted an International Nonproprietary Name (INN) of “dorocubicel” on the INN Recommended List issued by the World Health Organization (WHO) – The U.S. Food and Drug Administration (FDA) has granted UM171 Cell Therapy...

ExCellThera announces new UM171 data to be presented at ASH 2023

by admin | Nov 3, 2023 | English

MONTREAL, November 3, 2023 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and fitness, announced today several UM171 presentations, including an oral session on new data from Phase 2 studies of investigational UM171 cell therapy in...

UM171-Expanded Cell Therapy improves outcomes compared with other graft sources: Real-world evidence

by admin | Aug 8, 2023 | English

MONTREAL, August 8, 2023 – Cordex Biologics Inc., an ExCellThera Company, announced today the recent publication in Blood Advances from the American Society of Hematology of results from a safety and efficacy retrospective analysis comparing outcomes of patients...

Recent Posts

  • ExCellThera Announces International Non-proprietary Name and New Orphan Drug Designation for UM171 Cell Therapy
  • ExCellThera announces new UM171 data to be presented at ASH 2023
  • UM171-Expanded Cell Therapy improves outcomes compared with other graft sources: Real-world evidence

Recent Comments

No comments to show.

Archives

  • June 2024
  • November 2023
  • August 2023

Categories

  • English